📝 This Week's Analysis
Johnson & Johnson is one of the most enduring blue-chip dividend payers in the world. After spinning off its consumer products division (Kenvue) in 2023, JNJ is now a pure-play pharmaceutical and medical device company — a cleaner, higher-margin business with stronger growth prospects.
At the current price, our Graham formula yields an intrinsic value significantly above the market price. With EPS of $9.98, an expected 5-year growth rate of 6.5%, and the current bond yield at 5.1%, the math suggests JNJ trades at a meaningful margin of safety. That's unusual for a company with 62 consecutive years of dividend growth — a Dividend King.
The pipeline is the real story: JNJ has a deep oncology and immunology portfolio, with several blockbuster drugs still in peak growth phases (Darzalex, Stelara successor strategies) and a medical tech segment that grows steadily with aging demographics.
The post-Kenvue JNJ is a cleaner story. The messy consumer-product litigation overhang has been largely ring-fenced. What's left is a focused, high-quality pharma and medtech business — exactly the kind of durable compounder that value investors have historically been rewarded for holding.
💡 Why This Matters
Most investors think "safe stocks" have to be boring and overpriced. JNJ challenges that assumption. Here's the deal: when a company has raised its dividend for 62 straight years — through recessions, pandemics, wars, and rate hikes — it's telling you something profound about the durability of its cash flows.
The Graham formula is deliberately conservative. It doesn't care about hype or "moats" — it just asks: given the earnings, the growth, and what bonds pay right now, is this stock cheap? Right now, the formula says yes.
A 49.7% payout ratio means the dividend is extremely safe — they're paying out less than half their earnings. The rest gets reinvested or returned via buybacks. This is the kind of stock Graham would have called a "defensive" holding — suitable for investors who want to sleep at night while still beating inflation.
⚠️ Key Risks to Consider
- →Talc litigation — ongoing mass-tort liability from legacy baby powder claims could result in multi-billion dollar settlements.
- →Stelara biosimilar competition began in 2025, which may pressure near-term revenue as patents expire.
- →Patent cliffs on key drugs could weigh on growth beyond 2027 without pipeline success.
- →Post-Kenvue business is more concentrated in biopharma, adding sector-specific regulatory risk.
- →Currency headwinds — roughly half of revenue is international, making USD strength a consistent drag.
📣 Share This Analysis
Found this useful? Share it with your investing circle.
🧮 Graham Analysis
V = EPS × (8.5 + 2g) × 4.4 / YAnalysis based on data as of March 17, 2026. Verify inputs before making investment decisions.
Run Your Own Screening →💰 Dividend Data
Not financial advice. This analysis is for educational purposes only. The Graham formula is one tool among many. Always do your own research before investing.